Goldman Sachs Maintains Buy on SpringWorks Therapeutics, Raises Price Target to $49
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins maintains a Buy rating on SpringWorks Therapeutics (NASDAQ:SWTX) and raises the price target from $43 to $49.
July 20, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs maintains a Buy rating on SpringWorks Therapeutics and raises the price target from $43 to $49.
The raised price target by Goldman Sachs indicates a positive outlook for SpringWorks Therapeutics. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100